Phase 1 N=17 Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
Prostate Cancer · Prostatic Neoplasm
Primary: Maximum Tolerated Dose (MTD) — 40; 42.5 gray (Gy)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 3 N=122 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Prostate Adenocarcinoma
Primary: Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI — 92; 127 number of tumor lesions
Phase 2 N=25 FACBC for Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: The Presence of Cancer Tissue Inside of the Prostate Bed — 13; 8; 1; 0 Participants
Phase 3 N=840 Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Prostate Cancer
Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020
Phase 2 N=20 Sulforaphane in Treating Patients With Recurrent Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: Proportion of Patients Who Achieve a 50% Decline in Prostate-Specific Antigen (PSA) Levels — 5 percentage of participants
Phase 3 N=109 Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Metastatic Prostate Cancer
Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants
Phase 2 N=6 Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With a Toxicity — 6; 7; 24 Percentage of participants
Phase 2 N=10 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Recurrent Prostate Carcinoma
Primary: Average SUVmax of Ga68 PSMA Uptake Outside the Expected Normal Biodistribution — 12.4 SUVmax
Phase 3 N=61 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Prostate Adenocarcinoma · PSA Failure · Recurrent Prostate Carcinoma
Primary: Confirmation of Prostate Cancer Recurrence by 68Ga-PSMA-11 PET/CT — 46; 15 Participants
Phase 3 N=346 Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
Prostate Cancer
Primary: True Positive Rate for Detection of Tumor Location in Lymph Nodes Confirmed by Histopathology/Biopsy, Clinical and Conventional Imaging Follow-up
Phase 2 N=100 Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
Prostate Cancer
Primary: Number of Patients With Late Treatment-related Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) — 12 Participants
Phase 3 N=385 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Prostate Cancer
Primary: Positive Predictive Value (PPV) on a Per-patient Basis With Histologic Validation — 0.90 percentage of times value is true
Phase 2 N=23 Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: PSA Response — 0 participants
Phase 2 N=93 FACBC PET/CT for Recurrent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With True Positive Scans Within the Prostate Bed — 55; 41 participants
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Phase 2 N=49 Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
Recurrent Prostate Cancer · Stage I Prostate Cancer · Stage IIA Prostate Cancer
Primary: Number of Patients With PSA Response, Defined as a 50% or Greater Decline in the Serum PSA Level — 0; 28; 4; 3 participants
Phase 3 N=165 FACBC Outcomes for Post Prostatectomy
Prostate Cancer
Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants
Phase 2 N=27 Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…
Phase 2 N=20 Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer
Primary: Rate of Rise of Serum PSA — 0.0825 Nanograms Per Milliliter
Phase 2 N=41 Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 2 N=74 Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
Prostate Cancer
Primary: Median Relapse-Free Survival Time (Biochemical or Clinical) — 45.3 months
Phase 1 N=6 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Prostatic Neoplasms · Prostatic Cancer
Primary: Number of Participants With Dose-Limiting Toxicities — 0; 0 Participants
Phase 2 N=27 Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Prostate Adenocarcinoma · PSA Progression · Recurrent Prostate Carcinoma
Primary: Number of Lesions Detected by Investigational Imaging Agent — 31; 20 lesions
Phase 2 N=102 Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Prostate Cancer
Primary: Relapse-free Survival — 13; 10 months
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Phase 2 N=40 Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Prostate Cancer
Primary: Time to Disease Progression — 15.2 weeks